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Irreversible electroporation (IRE) is a promising new minimally invasive modality for the ablation of solid tumors. Unlike the current leading thermal
ablation modalities, such as radiofrequency ablation (RFA) and cryoablation, IRE uses nonthermal electric energy to irreversibly destabilize cell mem-
branes, resulting in focused cell death. Over the past 7 years, IRE has been emerging as a novel ablation tool by using the effect of an applied electric ﬁeld
to kill cancer cells, without damaging the surrounding extracellular matrix, vessels, nerves, and neighboring normal tissue. Although IRE has been
investigated for a short period of time, its potential use for cancer and tissue ablation has been receiving growing attention leading to a considerable
number of studies on its validity and safety, including recent in vivo animal and human studies.
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Irreversible electroporation (IRE) is a novel nonthermal ablation
modality with promise for revolutionizing the treatment for local
solid tumors.1–5 With the growing demand for alternative and less
invasive treatments for localized tumors, we have seen the devel-
opment and investigation of several tissue ablation modalities,
including radiofrequency ablation (RFA), microwave ablation, and
cryoablation. Although these modalities have been efﬁcacious, they
have some disadvantages owing to their reliance on thermal energy
for creating cell death.1,4 IRE is novel in that it does not use thermal
energy, but electrical energy to produce focused cell death while
sparing the normal extracellular matrix, nearby vessels, and struc-
tures, while allowing for rapid normal tissue regrowth.1–10 Unlike
thermal ablation modalities, IRE does not require signiﬁcant consid-
eration for dissipation of thermal energy, or heat sink, and has less
complications relating to damage of normal soft tissue, eliminating a
major cause of treatment failure.2,3,5,10,11 Additionally, IRE treatment
time is signiﬁcantly shorter than traditional thermal ablation mo-
dalities, in low minute ranges, and may allow for treatment of
considerably larger lesions than thermal ablation modalities.7,12
Although IRE has been investigated and utilized for only the past
7 years, its potential use for cancer ablation has been receiving
growing attention leading to a considerable number of studies on
its safety and efﬁcacy. IRE has demonstrated effective cell death in
normal tissue, cancer cell cultures, in vivo animal studies, and
human clinical studies.13–27 IRE is now being studied with great
enthusiasm in several organ systems with promising data.Interventional Radiology, Department of Radiology, Ronald Reagan Medical Center at UCLA,
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Electroporation is a technique in which strong electrical ﬁelds
are used to create nano-sized pores in a cell’s membrane, per-
meabilizing the cell membrane, and disrupting intracellular ho-
meostasis.12 The formation of pores by electroporation can be
reversible or irreversible. Although reported as early as the 1750s,
electroporation has been an important tool in medicine and
research for only the past 30 years.12 Reversible electroporation has
been utilized in many medical applications, including electro-
genotherapy to deliver genes into cells for gene therapy and also
electrochemotherapy to deliver chemotherapeutic drugs into cells
as an alternative method of treating solid tumors.12,28–34 However,
if the applied electric voltage is above a certain threshold, it leads to
a larger potential gradient and the cells are unable to seal the
formed pores and the result is cell death.35
Until 7 years ago, IRE was merely considered an undesirable
side-effect of reversible electroporation as investigators were
attempting to treat and cure cells and causing cell death would
have been considered a failed attempt. Until recently, irreversible
disruption of cell-membrane integrity by IRE had only found a
practical use in microbial inactivation in the food industry.36–39
Rubinsky’s group2,3,5 however, introduced the use of IRE as a
method to deliberately induce irreversible disruption of cell
membrane integrity in order to cause cell death. Over the past 5
years IRE has been emerging as a signiﬁcant medical tool in its own
right by using the effect of an applied electric ﬁeld to kill cancer
cells, as well as other undesirable tissue. IRE has demonstratedDavid Geffen School of Medicine, Los Angeles, CA, USA
, Ronald Reagan Medical Center at UCLA, David Geffen School of Medicine at UCLA,
vier. Open access under CC BY-NC-ND license.
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with the ﬁrst in vivo use of IRE in animal studies reported by Edd
et al3 in 2006, and the ﬁrst in vivo use reported in humans by Pech
et al20 in 2010.
The science behind IRE
IRE takes advantage of the electric potential gradient that exists
across cell membranes to create permanent pores in the cell
membrane. The IRE generator sends electric energy pulses that
alter the cell’s transmembrane potential, causing disruption of the
lipid bilayer, and creating permanent nano-sized pores that irre-
versibly increase the permeability of the cell membrane .2,3,5,12,41,42
The result is focused apoptotic cell death within seconds as the cell
loses its ability to maintain homeostasis, and the creation of a well-
demarcated region of ablation, with a sharp boundary between the
treated and untreated areas.3,7Molecular surgery
Recently, Lee et al43 demonstrated nanometer-sized pores
created by IRE using scanning electron microscopy. For the ﬁrst
time, they showed various sizes of nanopores formed on swine and
rabbit liver cell membrane (Fig. 1). Esser et al41,42 also shed light on
the cellular scale phenomena, describing the electrical ﬁelds and
the dynamics of pore formation during IRE. He used a multicellular
system model composed of irregularly shaped liver cells at a 100-
mm spatial scale and a multiscale liver tissue model at a 200-mm
spatial scale.41,42 Golberg et al44 compared IRE with “molecular
surgery” because only the cell membrane in the treated area is
affected while other molecular structures in the tissue are
spared.12,45Fig. 1. Scanning electron microscopy image demonstrating multiple nano-sized pores
(arrows) on the cell membrane of swine liver after ablated with IRE.Tissue ablation by IRE versus thermal ablation modalities (apoptosis vs.
necrosis)
Tissue ablation by thermal ablation modalities creates central
necrosis, surrounded by a gradually increasing border of cell death
with time as heat or cold dissipates at the peripheral border of the
intended ablation zone.1,5,46,47 Unlike these thermal ablation tech-
niques, IRE causes complete cell death without the use of signiﬁ-
cant thermal energy, and without the associated inﬂammation and
immunoreaction.48
Lee et al6,7 were the ﬁrst to demonstrate that cell death created
by IRE has increased positive BAX (BCL-2 oncoprotein) and terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay
staining compared with normal adjacent tissue, indicating the role
of apoptosis in cell death created by IRE (Fig. 2). This is in contrast to
the thermal ablation modalities where RFA creates coagulative
necrosis, and cryoablation creates cell membrane rupture, leading
to central necrosis of the ablated region.1,4,12 Utilizing immortal
human cervical adenocarcinoma HeLa cells, Zhou et al48 were again
recently able to demonstrate the principle behind IRE-induced
apoptosis, showing that low-voltage IRE with more pulses
induced the tumor cells to undergo apoptosis and effectively
eliminate the HeLa cells. The signiﬁcance is that the application of
these short strong electrical pulses with IRE has little effect on the
temperature of the treated tissue and the Joule heating induced
temperature elevation in tissue by IRE reaches levels that are not
harmful to surrounding tissues.2,49
Additionally, Lee et al7 showed hepatocellular regeneration as
early as 24 hours after IRE ablation, with another study by Rubinsky
et al10 demonstrating marked cellular tissue repair seen 14 days
after IRE. These ﬁndings further support the role of IRE induced
apoptotic cell death as apoptotic cells are promptly removed by
immune cell derived phagocytosis and replaced by innate cellular
regeneration.7,10 This is in contrast to coagulative necrosis and
protein denaturation induced by thermal ablation modalities,
where necrotic cell death does not get replaced by intrinsic cellular
regeneration but rather by ﬁbrosis and scarring of cellular and
tissue remnants. It is noteworthy that although immune cells play a
role in the rapid resolution and healing of ablation with IRE, Al-
Sakere et al50 found that treatment success is not dependent on
the immune system, although a tumor-speciﬁc immune response
may be invoked.9,50,51
IRE spares the surrounding extracellular tissue
IRE’s largely apoptotic effect lends to its promising clinical fea-
tures, including the ability to affect speciﬁc cells, while sparing the
surrounding extracellular tissue structure, and leaving blood ves-
sels, bile ducts, the urethra, and nerves intact to function nor-
mally.6–10,16,52–56 We believe that these structures are left fairly
unharmed, because their higher collagenous connective tissue and
elastic ﬁber contents lack a normal cellular membrane where IRE
can create pores. This hypothesis is supported by evidence of mild
vasculitis found in vessels within the IRE ablation zone, likely due
to damage of endothelial cells lining the vessels, which lack
collagenous and elastic ﬁbrous tissues.6 Another explanation that
may explain the sparing of these structures is that gap junctions
found within the cellular structure of these structures allow the
electric currents of IRE to travel through the gap junctions from cell
to cell without affecting the integrity of the cell membrane or
surrounding connective tissue structures.6 Speciﬁc to neural tissue,
Schoellnast et al53,57 demonstrated that nerves exposed to IRE were
shown to maintain intact endoneurium and perineurium archi-
tecture, with Schwann cell proliferation, in contrast to nerves
exposed to RFA which demonstrate coagulative necrosis. These
Fig. 2. Cell death by necrosis versus apoptosis. (A) Liver necrosis caused by radiofrequency ablation (RFA). (B) Apoptotic cell death caused by irreversible electroporation (IRE) – dark
brown stains are positive for TUNEL assay. TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling.
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regeneration that is not present in nerves exposed to RFA.53,57
IRE is not affected by heat sink
Because IREdoesnotdependonheating for its ablativeeffects, it is
not affected by heat sink, which is the cooling effect from blood ﬂow
that often hinders the full effect of thermal ablation modalities such
as RFA for targeting ablation of hypervascular tumors or tumors near
large vasculature.4,52 This translates to the potential ability to
completely ablate tumors up to the vessels without losing heat or
cold via bloodﬂow, as seen inRFAandcryoablation, respectively. This
also means that IRE can ablate peri-vascular tumors such as a large
hepatocellular carcinoma (HCC) around the portal vein or hepatic
vein, which were considered nonablatable by RFA in the past.7–10
The IRE system and treatment protocol
IRE uses a direct current (DC) generator that creates short pulses
of high voltage electric current to create irreversible pores in the
cell membrane, thus, inducing apoptotic cell death in a target tis-
sue.9 The procedure requires a medical device speciﬁcally designed
for clinical use and able to balance the delivery of high energy
pulses with patient and operator safety. In 2007, Bertacchini et al35
reported on the ﬁrst IRE system approved for clinical use. Safety is
an especially important concern with IRE because irreversibly
electroporating a target volume of 50 cm3 to 70 cm3, requires
generation of pulses of up to 3000 V of amplitude and currents up
to 50 A.35 The device must produce an electrical ﬁeld gradient in a
volume 40 cm3 that is at least 800 V/cm, which was determined by
Davalos et al2 to be the threshold for IRE in most cell types.
The IRE system (Fig. 3, NanoKnife; AngioDynamics, Queensbury,
NY,USA) consists of twomain components: an IRE generator and up
to six electrode probes. The generator can deliver between 100 V
and 3000 V of energy in 90–100 pulses, with a maximum pulse
length of 100 ms. The electrode probes are generally 15 cm in
length and 16–19 gauge in diameter, and are inserted in or around
the area of interest to be ablated. Two ormoremonopolar probes or
a single bipolar probe must be used at a time, and an electrical ﬁeld
is created between them in a series of microsecond pulses inducing
cell death. In vitro porcine data have shown that the bipolar probe is
capable of creating an ellipsoid ablation zone with axes of
approximately 30 mm and 15 mm.20,35 The number of probes thatare used during an IRE procedure is dependent on the size and
shape of the desired zone of tissue ablation. Also, because the
amplitude and the gradient of the ﬁeld depend on the applied
voltage as well as on the distance between the electrodes, the
treatment parameter for voltage is dependent on the distance be-
tween probes within the targeted tissue.20,35
IRE treatment is minimally invasive, and can be performed with
ultrasound (US) or computed tomography (CT) guidance. US, CT, or
magnetic resonance imaging (MRI) may also be used post-
procedurally to assess the extent of tissue ablation. The availability
of pre- and especially peri-procedural imaging with US and CT,
allows for accurate determination of tissue volume to be treated,
and appropriate treatment planning and positioning of the elec-
trodes.6,7 An electrocardiogram (ECG) synchronizer should be used
to synchronize IRE pulses with the refractory period of the cardiac
rhythm in order to minimize the risk of arrhythmias.14,20,35,58 The
overall time for the IRE treatment procedure is extremely short,
lasting minutes as ablation typically requires 90–100 pulses, cor-
responding to the same number of heart beats because IRE is
coupled to the cardiac rate.20,35
Traditional IRE protocols achieve ablation through a series of
unipolar electric pulses that result in signiﬁcant muscle contrac-
tions. Because IRE treatment requires the patient to remain
motionless, IRE is typically administered under general anesthesia
with administration of neuromuscular blocking agents, such as
atracurium or pancuronium, to prevent muscle contraction. Gold-
berg and Rubinsky59 have proposed a technique to mitigate the
volume of untargeted tissue that is vulnerable to muscle contrac-
tion during IRE. The authors suggest that surrounding a central
energized electrode with a series of grounded electrodes reduces
the volume of tissue exposed to electric ﬁelds with the potential to
induce contraction. This novel approach, which is based on the
Faraday cage concept, requires that at least 16 grounded electrodes
surround one superﬁcially inserted, energized electrode. Based on
Goldberg and Rubinsky’s59 model, this conﬁguration signiﬁcantly
reduces the volume of untargeted tissue that experiences con-
tractions. Upon clinical translation, this innovation may reduce the
amount of muscle relaxants that must be administered to achieve
sufﬁcient paralysis.59
Arena et al60 recently developed a slightly modiﬁed approach,
known as high-frequency irreversible electroporation (H-FIRE),
that utilizes high frequency, bipolar bursts to eliminate muscle
contraction, without sacriﬁcing the efﬁciency of cell death due to
Fig. 3. Current IRE system. (A) IRE generator from AngioDynamics Inc. (B) 16G Bipolar IRE probe. (C) 19G monopolar IRE probes. (D) Monopolar IRE probe spacer. (E) IRE generator
pedal. IRE, irreversible electroporation.
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pulses of IRE, and H-FIRE at 250 kHz or 500 kHz. Although IRE led to
characteristic muscle contractions, H-FIRE treatment at either fre-
quency did not produce visual or tactile evidence of muscle
contraction. Histopathological examination of the tissues revealed
that H-FIRE at 250 kHz or 500 kHz was indistinguishable from IRE
with respect to ablation efﬁcacy and precision.60 The clinical
application of H-FIRE may eventually eliminate the need to
administer neuromuscular agents during the IRE procedure.
Treatment protocol
Although the IRE procedure is relatively simple to perform,
successful usage and outcome requires development of a treatment
protocol based on a thorough understanding of how currents ﬂow
within various tissues. Treatment planning is crucial for IRE. Until
recently, treatment planning to ensure complete ablation of the
desired lesion consisted of mathematical formulations based on a
deterministic model, using a deterministic single value for the
amplitude of the electric ﬁeld required for causing cell death.45 Thismodel assumed that IRE is associated with a single value of local
electric ﬁeld current and heat distribution during pulse application.
However, as Golberg et al44 explains, this is only correct when the
cell population is homogeneous and uniform, which is not the case
for tumor cells which are conversely heterogeneous and in different
stages of development.
IRE outcome success depends on a number of parameters
including the number, length, and shape of electric pulses, the in-
terval between pulses, ﬁeld amplitude, and polarity.44 Especially
important are the cell parameters of type, morphology, age, and
size.5,61–66 Past studies have described that the electric ﬁelds which
occur in tissue ablation can be complex and variable, and that the
treatment protocol must take into consideration the electric ﬁeld
distribution within the tissue which will signiﬁcantly direct the
effect of IRE, depending on parameters such as the electrode
conﬁguration, pulse parameters, and tissue heterogeneities .2,45
The point is to use these parameters in order to ensure that the
electric conditions created will destroy all the undesirable cells
throughout the entire volume of target tissue, and leave the normal
tissues we want to maintain unharmed. Thus Golberg et al44 have
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that can take these parameters into consideration. It has long been
known for example that in a population of aging cells, there is a
statistical distribution, correlating cell survival to electroporation
parameters.67,68 Therefore, Golberg et al44 use this model to adapt
the previously employed deterministic model, into a novel statis-
tical model of IRE-induced cell death to be used in making a more
accurate type of treatment planning for more complete ablation of
cancerous tumor cells in tissue.44
Ben-David et al69 set out to determine the optimum parameters
to perform precise liver ablation by IRE. US-guided IRE ablationwas
performed on 25 live porcine livers. The investigators systemati-
cally varied the number of pulses (20–90), length of pulses (20–
100 ms), voltage (2250–3000 V), distance between electrodes (1.5–
2.5 cm), and length of active electrode exposure (1.0–3.0 cm). The
study concluded that all parameters were inﬂuential on IRE out-
comes, and that accurate zones of ablation could be achieved by
precise calibration of IRE protocols.69 Also described by Ben-David
et al69 and based on our personal experience, the most challenging
parameter to optimize is accurate electrode placement. Evenwith a
laparotomy approach, an accurate electrode placement is difﬁcult
to achieve with current monopolar electrode (19 gauge) which is
very ﬂimsy and unstable when it is inserted. As the IRE ablation
outcome is absolutely dependent on electrode distance and
conﬁguration within the tumor, a more innovative method of
accurately placing the electrodes is needed. A new design of elec-
trode, electrode stabilizer, and multi-imaging modality guidance
have been implemented and currently active research projects are
being conducted.
Safety considerations
Recently, Raffa et al70 demonstrated that performing IRE in the
presence of ﬁbril boron nitride nanotubes (BNNTs) lowers the
necessary voltage threshold required to cause tumor cell death.
BNNTs consist of hexagonal arrangements of B and N atoms with
the potential to amplify an electrical ﬁeld within a cell. Comparing
IRE in the absence and in the presence of BNNTs revealed that
BNNTs signiﬁcantly decrease the required voltage to produce cell
death. Of note, IRE at 800 V/cm was 2.2 times more effective at
causing cell destruction when performed in the presence of
BNNTs.70 These results suggest the potential use of BNNTs to in-
crease the safety of IRE procedures by lowering the voltage
threshold required to cause tumor cell death.
Need for ECG synchronization
Considerations of the IRE procedure and of appropriate patient
selection include the need for use of ECG synchronization, muscle
relaxant, and placement of several electrodes in cases of larger
tumors.14,20,58 The likelihood of an IRE treatment to cause
arrhythmia depends on a number of factors including: the applied
pulse voltage, pulse repetition rate, length and number of pulses,
and the distance between the electrodes and the heart.58,71
Therefore, synchronization of treatment delivery with the re-
fractory period of the cardiac cycle is important, especially when
there is not enough conﬁdence that IRE cannot determine a current
density lower than ﬁbrillation threshold of the myocardium.35,58
In previous studies, IRE has been performed using parameters of
2000–3000 V at a high rate of 240 pulses per minute (PPM). du Pré
et al72 has recently demonstrated that IRE is unlikely to cause
damage to coronary arteries, even when the treatment is targeted
toward the coronary artery region.72 Notwithstanding the absence
of damage to critical cardiac structures, there are lingering safety
concerns regarding the use of IRE’s high electric energy in treatingtumors located near the heart. These types of strong electric pulses
may potentially cause arrhythmias such as ventricular ﬂutter and
ﬁbrillation especially when the electrical pulses are delivered
during the “vulnerable period” of the heart cycle or in patients with
underlying arrhythmias.58,73,74
With the demand for an effective local ablative therapy for
treating tumors located close to the heart, such as a perihilar mass
or a hepatic tumor at the dome, Mali et al73 developed an algorithm
for the synchronization of IRE pulse delivery with ECG. This is
possible when the algorithm for IRE pulse delivery is based on early
detection of the QRS complex, including the QR junction slope and
R wave peak of the ECG signals, which is prior to the vulnerable
period and is the safest time for pulse delivery.73 This method of
synchronizing IRE pulses with ECG has shown to be an effective and
reliable tool for detecting QRS and preventing pulses from being
delivered in case of abnormalities in heart rate.58,73 Thomson et al21
recently conducted a prospective, nonrandomized cohort study of
IRE ablation of liver, kidney, and lung tumors in human patients.
Four out of eight patients experienced transient ventricular
arrhythmia when IRE was not synchronized with ECG. However, in
procedures utilizing ECG synchronized IRE, there were only two
cases of transient ventricular arrhythmia in a sample of 30 pa-
tients.21 Thus, synchronization of pulse delivery with ECG presents
a signiﬁcant improvement from existing procedures of electropo-
ration delivery with respect to the safety of the patient.21,58
Recently, we have conducted a preclinical study comparing the
effectiveness and safety of the ECG synchronized and non-
synchronized IRE ablation. The synchronized IRE ablation created a
similar sized ablation zone compared with nonsynchronized IRE
with a markedly improved safety proﬁle (unpublished data). Even
the ablation performed at the dome of the liver did not cause any
dysrhythmias.
In summary, based on several clinical and preclinical studies,
synchronized IRE is a safe and effective way to prevent any IRE-
associated cardiac arrhythmia. However, this requires additional
studies and therefore, each IRE ablation should be optimized based
on each patient’s cardiac history and risk stratiﬁcation.
Pain control
Postoperative pain in IRE will be an important factor in overall
patient satisfaction of the procedure. Narayanan et al,75 whose past
report treated over 100 liver cancer patients with IRE,18 examined
differences in self-reported pain between HCC patients treated
with IRE versus those treated with RFA. The IRE treatment group
consisted of 21 patients with a total of 29 intrahepatic lesions,
whereas the RFA group included 22 patients with 27 foci of cancer.
The level of pain experienced by each patient was assessed by self-
evaluation and the cumulative application of patient-controlled
analgesia (hydromorphone) in the 24 hours after surgery. Upon
analysis, there were no signiﬁcant differences in self-reported pain
or the amount of self-injected analgesia between patients treated
with IRE and those treated with RFA. These results suggest that
patients will tolerate IRE tumor ablation at least as well as they
tolerate modalities currently in use.75 Kasivisvanathan et al15
recently reafﬁrmed this conclusion by describing a case of suc-
cessful use of IRE for the focal ablation of a tumor at the porta
hepatis.
Research, clinical developments, and potential for oncological
treatment
IRE is now being studied with great enthusiasm in several organ
systems as a nonthermal, minimally invasive tissue ablation mo-
dality for ablating tumors and other undesired tissue with
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IRE can be used to destroy substantial volumes of tissue without
inducing thermally damaging effects, several researchers have
conﬁrmed these ﬁndings in small and large animal models in the
liver,2,3,6,7,76 breast,77 prostate,9 brain,78–83 pancreas,84,85 kidney,86
lung,87 and in implanted mouse sarcomas,50,51 using a variety of
pulse parameters.
Data from IRE performed in clinical in vivo human trials have
been presented at several international conferences, published ar-
ticles, and multiple case reports over the past few years, predom-
inantly focusing on treatment of tumors within the liver, lung,
prostate, pancreas, and kidney. These studies have evaluated the
safety and feasibility of performing IRE for tissue ablation in human
patients, showing a favorable safety proﬁle and heralding the
anticipation of further human studies on the way.
The following is a summary of oncologically driven preclinical
and also clinical human studies using IRE for tumor ablation.
Liver and metastases to liver
Preclinical liver studies
Lee et al88 demonstrated the efﬁcacy of IRE in treating large
hepatic tumors in vivo in a study consisting of 35 New Zealand
white rabbits with VX2 tumors transplanted within their livers. Of
these, 10 rabbits were subjected to single IRE application, 10 rabbits
underwent multiple IRE applications, and 15 rabbits served as a
control group. After all specimens in each treatment group had
undergone ablation, the respective livers were evaluated with US,
CT, and immunohistochemical analysis. Lee et al88 found that
multiple IRE applications were able to produce complete tumor
ablation without any complications.88
Clinical liver studies
Kingham et al16 conducted a 10-month retrospective study of 28
human patients treated with IRE for 65 malignant hepatic tumors.
Patients underwent contrast-enhanced CT or MRI postoperatively,
at 1–3 months, and at 6 months following the procedure. At 6
months, four tumors had experienced a recurrence. There was only
one postoperative portal vein thrombosis despite the presence of
41 tumors within 1 cm of amajor hepatic vein or portal pedicle. At 6
months, there was no mortality associated with the treatment. The
authors concluded that IRE is a safe treatment option of peri-
vascular malignant hepatic tumors that may not be treated with
conventional modalities.16
Cannon et al27 reported on IRE of hepatic tumors near vital
structures, with 44 patients undergoing 48 total IRE procedures,
including 20 colorectal metastases, 14 hepatocellular, and 10 other
metastases. They reported initial success in all 46 (100%) of the
treatments, with local recurrence free survival at 3 months, 6
months, and 12 months of 97.4%, 94.6%, and 59.5%, respectively.
They noticed a trend toward higher recurrence rates with ablation
of tumors over 4 cm (HR 3.236, 95% CI: 0.585–17.891; P ¼ 0.178).
Five patients had nine adverse events, of which three were thought
to be possibly related to the IRE procedure, including neurogenic
bladder, abdominal pain, and ﬂank pain, although all complications
resolved within 30 days.
Pancreas
Preclinical pancreatic studies
Prior to the advent of IRE, the range of options for the nonin-
vasive treatment of locally advanced pancreatic cancer wasessentially nonexistent due to the high risk of pancreatitis and
damage to critical adjacent vessels.85
In a study by Charpentier et al,84 four domestic female swine
were subjected to IRE of a normal pancreas, using two monopolar
probes spaced 9–15 mm apart. Ninety pulses of 1500 V/cm were
delivered for each ablation, with no procedure related complica-
tions. Three animals in which probes had been spaced at intervals
of 10 þ/– 1 mm showed evidence of irreversible ablation by gross
appearance and triphenyltetrazolium chloride (TTC) staining. The
only animal inwhich probes had been spaced at intervals of 15 mm
did not show evidence of irreversible ablation at 2 weeks. This was
likely secondary to the relatively low voltage from wider probe
spacing, which mainly results in reversible electroporationwithout
cell death. These ﬁndings suggest that IRE appears to be a safe
method for pancreas tissue ablation, with staining by TTC able to
predict the extent of the IRE ablation zone within 2 hours of
treatment.84
Bower et al85 also explored the utility of IRE in the pancreas
through a swine model. Four out of six total pigs successfully un-
derwent IRE, whereas the procedure was aborted in two pigs
because a stable current could not be maintained after multiple
attempts. Pathological examination conﬁrmed destruction of tissue
in the ablation zone with sparing of surrounding vasculature. There
were no complications other than transient increases in serum
amylase and lipase postoperatively.
In a recent study, José et al89 demonstrated the potential utility
of IRE in treating pancreatic ductal adenocarcinoma (PDAC). Forty
athymic mice were each implanted with 5  105 human pancreatic
adenocarcinoma cell line BxPC-3 BxPC-3-Luc cells to generate
orthotopic human pancreatic cancer xenografts. In the treatment
group consisting of 24 mice, tumors were subject to IRE once they
had grown to approximately 2–5 mm in diameter. The control
group of 16 mice underwent a sham operation devoid of IRE.
Twenty ﬁve percent of mice in the treatment group demonstrated
complete tumor ablation. However, 19% of treatment mice indi-
cated tumor regrowth at 30 days following surgery. Median sur-
vival time increased from 42 days in untreated mice to 88 days for
mice who had undergone IRE. PDAC is devastating cancer with a 5-
year survival rate that is less than 5%.89 Though the results of this
study are not perfect, they provide great hope for treatments of
advanced human cancer cases that are currently inoperable.
Clinical pancreatic studies
In the ﬁrst reported application of IRE to the treatment of human
pancreatic cancer, a prospective multi-institutional pilot conducted
by Martin et al17 evaluated the utility of IRE in treating locally
advanced pancreatic cancer. Of 27 patients who underwent treat-
ment, 26 were treated invasively and one was treated percutane-
ously due to a history of multiple past surgeries in the same region.
Nineteen patients were subject to in situ IRE, whereas the others’
treatment regimen consisted of IRE in addition to either left-sided
(n¼ 4) or pancreatic head (n¼ 4) resection. With the exception of a
single mortality, there were no postoperative complications. All
patients who completed 90-day follow-up experienced successful
ablation of all tumors with no recurrences.17 Though these results
must be more conclusively established in larger scale trials, the
success of this study indicate that IRE as one of only a few options
available to patients with locally advanced pancreatic cancer.
Following this study, Bagla and Papdouris13 reported the applica-
tion of percutaneous IRE to the treatment of a nonmetastatic, sur-
gically unresectable pancreatic adenocarcinoma in a 78-year-old
patient. As in the previous study, MRI conﬁrmed a successful
ablation with no recurrence and decreasing cancer antigen 19–9
level at 6-month-follow-ups.13
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patients for downstaging and control of unresectable locally
advanced pancreatic cancer. Of these, three patients had metastatic
cancer and were intolerant of chemotherapy, and 11 had disease
localized to the pancreas. Previous to IRE, 11 patients had received
radiation and three patients had received chemotherapy. Tumor
sizes ranged from 2.5 cm to 7 cm with a median of 3.3 cm.
Following IRE, all patients were found to have patent vasculature in
the regions exposed to treatment. There were no deaths attributed
directly to the IRE procedure, with spontaneous pneumothorax and
pancreatitis representing the only complications encountered.25
Martin et al26 recently reported results of a prospective, multi-
institutional evaluation of 54 patients who underwent IRE for
unresectable pancreatic cancer, including 35 patients with
pancreatic head primary and 19 patients with body tumors. Of
these, 19 patients underwent margin accentuation with IRE and 35
patients underwent in situ IRE. Forty nine (90%) patients had pre-
IRE chemotherapy alone or chemoradiation therapy for a median
duration 5 months, and 40 (73%) patients underwent post IRE
chemotherapy or chemoradiation. The authors found that the 90-
day mortality in the IRE patients was 1 (2%). Additionally, in a
comparison of IRE patients to standard therapy, they report an
improvement in local progression-free survival (14 months vs. 6
months, P ¼ 0.01), distant progression-free survival (15 months vs.
9months, P ¼ 0.02), and overall survival (20 months vs. 13months,
P ¼ 0.03), showing potential to achieve greater local palliation and
potential in improved overall survival compared with standard
chemoradiation–chemotherapy treatments.26
Lung
The proximity of the lung to the heart can pose a contraindi-
cation to ablative techniques such as RFA that result in central
thermal sinks within themediastinum. Because IRE is a nonthermal
technique, its clinical implementation would present newfound
hope for patients with thoracic tumors that are currently not can-
didates for surgical treatment.90
Preclinical lung studies
In the ﬁrst study to evaluate the efﬁcacy of IRE for the ablation of
lung tissue, Dupuy et al90 created 15 percutaneous ﬂuoroscopy-
guided IRE lesions in the lungs of nine anesthetized domestic
swine. Radiographs and high-resolution CT were utilized to eval-
uate the animals prior towhen each lungwas harvested to facilitate
histological examination. Microscopically, the parenchyma subject
to IRE demonstrated well-demarcated alveolar damage with
ﬁbrosis and inﬂammatory inﬁltration. As expected, there was no
damage to bronchioles and blood vessels within the ablative
zone.90 Within months of this initial study, Deodhar et al87 con-
ducted a similarly designed study, also involving swine, to reafﬁrm
the successful use of IRE for the ablation of lung tissue.87
Clinical lung studies
Usman et al22 reported the ﬁrst two cases of the application of
IRE to the treatment of lung neoplasms in humans. In the ﬁrst case,
a 33-year-old male presenting with recurrent pulmonary metas-
tasis of synovial cell carcinoma was treated with IRE, in order to
avoid collateral damage to adjacent pulmonary artery branches and
lobar bronchi. A lesion measuring 2.3 cm  2.4 cm  1.7 cm was
targeted and at the 2-month follow-up, the tumor had recurred, as
evident by uniform enhancement on contrast CT, and increased
metabolic activity on positron emission tomography. The second
patient was a 70-year-old female who was found to have a slowlyprogressing tumor in the immediate suprahilar region, showing
characteristics of both adenocarcinoma and squamous cell carci-
noma. The tumor was located superior to the azygous vein and
ventral to the trachea. Treatment of the 2.1 cm  1.9 cm  2.1 cm
tumor with IRE proved unsuccessful at the 2-month follow-up. At 9
months, CT scan images suggested invasion of the tumor into the
trachea. The patient passed away 1 year postoperation.22 The small
sample size of this report necessitates further investigations to
determinewhether IRE can treat lung cancer adequately, to prevent
recurrences and raise the life expectancy in patients with no other
surgical treatment options.22
Fanta et al23 demonstrated the efﬁcacy of IRE in the removal of
central nonsmall cell lung tumors in two patients. In the ﬁrst pa-
tient, a 3-cm epidermoid carcinoma completely obstructing the
right main stem bronchus had resulted in atelectasis. Pneumo-
nectomy was contraindicated due to poor lung function. The sec-
ond patient suffered from a 2-cm carcinoid tumor extending from
the right main stem bronchus to the carina, and preferred IRE due
to the risk associated with resection. In both cases, IRE was per-
formed through open thoracotomy with no complications. A CT
scan demonstrated successful ablation in both patients, with no
signs of recurrence present after 6 months.23
Renal
Preclinical renal studies
Tracy et al91 subjected eight Yorkshire pigs to IRE of the kidney.
Within 1 hour after ablation, renal cells in the zone of ablationwere
no longer viable, demonstrating diffuse desquamation of tubular
cells, eosinophilia, and nuclear condensation. Comparison of suc-
cessively harvested kidneys revealed that initially diffusely hem-
orrhagic legions progressed to smaller, acellular scars over the
course of 14 days. Concurrently, periablative regions that had
initially experienced patchy urothelial injury appeared to be un-
dergoing a process of repair.91
Deodhar et al86 conducted a similar study using a porcine
model, to evaluate the effects of IRE ablation on normal renal tissue.
CT-guided IRE was performed on 15 female swine to produce a total
of 29 ablations. CT imaging immediately after the procedure
revealed a hypodense nonenhancing lesion that persisted for up to
7 days after surgery. Connective tissue, including the pelvic extra-
cellular matrix and blood vessels, as well as the renal pelvis and
collecting system, remained intact in all cases.86 Wendler et al55
expounded on these studies by using MRI to evaluate the IRE
ablation of renal tissue. Histological analysis of targeted tissue
revealed IRE destruction of cortical glomeruli and tubules, but no
damage to supporting structures including collecting ducts, renal
calyxes, and the pelvis of medulla.55
Gastrointestinal (GI) tract
Preclinical GI Studies
The small intestine is particularly prone to collateral damage
during invasive and noninvasive procedures targeting gastroin-
testinal cancer. Phillips et al92 postulated that the tendency of IRE
ablation to spare the extracellular matrix would allow quicker
regeneration of mucosal cells. In turn, adverse side effects resulting
from IRE ablation would be shorter-lived than traditional pro-
cedures. Thirteen Sprague–Dawley rats were anesthetized, and
their intestines were exposed to 50–70 ms long 200 V pulses at a
frequency of 4 Hz. Histological analysis revealed that all cells in the
targeted area were completely ablated. Regeneration of the
epithelial layer was observed within 3 days, with development of
Natanel Jourabchi et al. / IRE in cancer treatment: A review 15distinct layers taking place by Day 7 postprocedure. These results
suggest that IRE may eventually be utilized to ablate abdominal
tumors in human patients with minimal collateral damage to
adjacent tissues.92
Schoellnast et al57 investigated the utility of IRE in ablating
perirectal tissue and the associated pathological effects on the
rectum wall. In six pigs, CT-guided IRE ablation was performed in
the presence of water-ﬁlled endorectal coils that prevented
displacement of the rectum wall. Five other pigs were subjected to
CT-guided IRE without endorectal-assisted ﬁxation of the rectum.
Subsequent pathological evaluation revealed that inﬂammation
and ﬁbrosis was more superﬁcial in pigs whose rectums had been
mobile and allowed to contract than in pigs whose rectum was
ﬁxed. Speciﬁcally, almost all lesions found in pigs with mobile
rectumswere limited to the external layer of themuscularis propria,
whereas all lesions in pigs with ﬁxed rectums were transmural. The
investigators concluded that by leaving the rectummobile and able
to contract, IRE ablation could be successfully performed on peri-
rectal tissue with minimal damage to the rectum wall.57
Brain
Preclinical brain studies
Garcia et al78 demonstrated the safety and efﬁcacy of IRE in
ablating canine brain tissue by performing IRE on the right tem-
poral lobe of a beagle. The dog did not suffer any side-effects
attributable to IRE, and histopathological examination revealed a
sharp boundary between normal and ablated tissue.78
Ellis et al81 built on the previous ﬁndings by successfully per-
forming intracranial IRE ablation of normal canine brain tissue. The
IRE electrodes were placed into a targeted area of the brain in three
dogs and delivered a series of short and intense electric pulses with
varying levels of voltage between dogs. An additional dog was
treated at an extreme voltage to determine the upper safety limits
of the procedure and one other dog was used as a sham control. US
was used at the time of the procedure to visualize the lesions
intraoperatively and MR imaging was used to estimate the volumes
of ablated tissue postoperatively. The lesion volume was found to
decrease with decreasing voltage of applied pulses and histological
examination revealed cell death within the treated volume with a
submillimeter transition zone between ablated and normal brain.
There were no apparent complications in the three dogs subjected
to therapeutic voltage ranges. The dog exposed to extreme voltages
suffered nonselective necrosis in the entire treatment ﬁeld, leading
to arterial thrombosis and subsequent lacunar infarction.
In a later study, Garcia et al80_ENREF_58 were the ﬁrst to utilize
IRE for the treatment of a spontaneous, inoperable malignant
intracranial glioma in a canine patient. In this case, IRE ablation
successfully reduced tumor volume, producing a sufﬁcient decrease
in intracranial pressure and associated improvement of neurolog-
ical function towarrant adjunctive fractionated radiotherapy. Serial
MRI examinations post IRE conﬁrmed full remission of the malig-
nancy, and the eventual death of the dog was due to progressive
radiation encephalopathy rather than complications from cancer.
These ﬁndings suggest a role for IRE in the treatment of malignant




In a recent study by Neal et al,77 human breast cancer tumors
were orthotopically implanted in the mammary fat pad of 11female Nu/Nu mice that were divided into treatment and control
groups. Seven tumor-bearing mice were treated with IRE and
tumor regression was observed in ﬁve out of seven of the MDA-
MB231 human mammary tumors in the course of 4 weeks after
treatment, with continued growth in controls.77 These ﬁndings
suggest that IRE could be an advantageous alternative to surgical
resection for breast conserving therapy.Cervix
Preclinical cervix studies
Zhou et al48 investigated the efﬁcacy of IRE at inducing death of
human cervical adenocarcinoma (HeLa) cells. The investigators
found that either a low number of high-voltage pulses or a high
number of low-voltage pulses were capable of causing HeLa cell
death. A low number of pulses of high-voltage IRE resulted in ne-
crosis of targeted human cervical adenocarcinoma cells. By
contrast, a higher number of pulses of low-voltage IRE induced cell
death through apoptosis, a preferred mechanism because of the
lack of accompanying inﬂammation and potential for tissue
regeneration posttherapy.48Prostate
Preclinical prostate studies
Onik et al9 studied IRE ablation in the normal prostate of six
males dogs and demonstrated complete cell destruction within the
IRE lesions, and rapid resolution of the lesions with marked
shrinkage within 2 weeks. Structures such as urethra, vessels,
nerves, and rectum were unaffected by the IRE application.9
Rubinsky et al40 studied IRE ablation of prostate adenocarci-
noma cells in vitro to determine the number, length, and ﬁeld
strength of IRE pulses required to produce complete human cancer
cell ablation. They found that the upper and lower limit bounds of
pulse length and number in a ﬁeld range of 2000 V/cm to 2500 V/
cm with a total of 90 pulses at 2500 V/cm for 100 ms separated by
100 ms could completely ablate prostate cancer cells without
inducing thermal damage.40 These ﬁndings suggest that IRE abla-
tion of the prostate appears to be safe and have advantages in the
clinical setting as compared to thermal ablation modalities,
including preservation of important structures in this delicate part
of the body.Sarcoma
Preclinical sarcoma studies
Al-Sakere et al51 studied the use of IRE for the minimally inva-
sive treatment of aggressive cutaneous sarcoma tumors implanted
in mice. Six mice, 6–8 weeks old, were inoculated subcutaneously
in the left ﬂank with cells from an LPB cell line, a
methylcholanthrene-induced C57Bl/6 mouse sarcoma cell line,
producing tumors of 4–5 mm in diameter in 9 days. They showed
that successful outcome of the IRE procedure is related to the
applied electric ﬁeld strength, the total pulse duration, and tem-
poral mode of pulse delivery. The best results were obtained using
plate electrodes to deliver 80 pulses of 100 ms at 0.3 Hz with an
electrical ﬁeld magnitude of 2500 V/cm across the tumor. Tumor
regression was conﬁrmed by histological studies, with complete
regression in 12 out of 13 treated tumors (92%) in the absence of
tissue heating.51
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Lee et al7 demonstrated that IRE can be performed as a real-time
percutaneous image-guided intervention, with observation and
measurements of the treated area acquired during real-time
monitoring correlating well with pathological measurement of
the lesion. This is in contrast to thermal ablation techniques such as
RFA and cryoablation, which create hyperechoic microbubbles from
the thermally injured tissue in US images, signiﬁcantly hindering
the possibility of real-time monitoring.93,94
Lee et al6,7 showed that IRE creates a spherical hypoechoic area
of ablation during and immediately after IRE in US images, with no
lesion-obscuring hyperechoic gas, that lasts up to 24 hours after
which the area of hypoechogenicity becomes hyperechogenic. They
postulate that the initial hypoechogenicity is likely to be caused by
increased intra/extracellular water content (edema and hyperemia)
in the area of ablation as a result of the disruption of cellular ho-
meostasis from the opening of transmembrane pores by the high
voltage of electroporation.6,7 Thus, ablation with IRE allows the
operator to visualize the effects of IRE with real-time US, thus
allowing for monitoring the effects of the electroporation pulses as
they are applied, and ideally making it possible to adjust protocol
parameters in real time to achieve desired results.
Following IRE, US representation of the ablation zone is dynamic
and continues to evolve for hours following the conclusion of the
procedure. Applebausm et al95 performed in vivo ablation of 16 pig
livers, and subsequently described the varying phases of the post
IRE US ablation zone. Within minutes, an initially hypoechoic and
well-demarcated zone gave way to a smaller and more isoechoic
representation on US. After 25–90 minutes, hemorrhagic inﬁltra-
tion within the tissue led to the development of a peripheral
hyperechoic rim around the isoechoic zone. Comparison to histo-
logical ﬁndings showed that the size of the external hyperechoic
rim at 90–120 minutes is the best predictor of the ablation zone
produced by IRE.95 Similarly, Schmidt et al96 afﬁrmed that US after
24 hours is more precise than US after 6 hours at localizing cell
death produced by IRE.96
Granot et al97 recently described the use of three dimensional
electrical impedance tomography (EIT) for real time monitoring of
IRE, with histological analysis showing good correlation between
the extent of tissue damage caused by IRE and EIT images. They
report that EIT is the only imaging technique based on a mea-
surement principle that is directly inﬂuenced by the electropora-
tion phenomenon through measuring passive electrical properties
of tissues. They argue that EIT may be the only feasible candidate
for real time imaging of electroporation with feedback control
purposes because other techniques, such as US, detect the indirect
consequences of electroporation and thus may be too slow for a
feedback scheme.97
Besides the use of these modalities for real time IRE ablation,
treatment outcome and extent of IRE ablation can also be conﬁrmed
with CTandMRI, showing creation of discrete andmeasurable areas
of ablation on CT and MR images in a 24-hour period.6,78,97,98 Lee
et al6,88 have published multiple studies on radiologic–pathologic
correlation of IRE-induced cell death. In a 2010 report,6 US guided
IRE of normal liver was performed on 16 Yorkshire pigs, 55 ablation
zones were created and imagedwith US, MRI, and CT and evaluated
with immunohistochemical analysis. IRE ablation zones were well
characterized with US, CT, and MR imaging, and real-time moni-
toring was feasible with US. IRE proved to be a fast, safe, and potent
ablative method, causing complete tissue death with full preser-
vation of periablative zone structures, including blood vessels, bile
ducts, and neighboring nonablated tissues.6
Guo et al99 recently demonstrated that like US, MR imaging
might be useful for the quantitative measurement of the size of IREablation zones. Fifteen rats were injected with gadopentetate
dimeglumine contrast agent, and subsequently subjected to IRE
ablation of the liver. Two hours after the procedure, MRI mea-
surements using conventional T1-weighted gradient echo
sequence (GRE) and inversion recovery sequence (IR)-prepared
GRE methods were performed. Upon harvesting of the livers, MRI
results were correlated with histologically determined areas of cell
death. The investigators found that cell death by IRE corresponds to
hyperintense regions measured on T1-weighted GRE images. Once
smaller hyperintense regions representing live penumbra tissue
were subtracted from the T1-weighted GRE measurements, the
remaining penumbra-nulled IR images proved to be very close
approximations of pathology-conﬁrmed ablation zones.99
Goldberg et al100 previously demonstrated in vitro that the
extent of decrease in the value of tissue galvanic apparent internal
resistance (GAIR) during IRE treatment is indicative of the efﬁ-
ciency of IRE100 In a more recent publication, Goldberg et al101
examined the in vivo GAIR changes of rat liver hepatocytes
exposed to IRE. The study found a 33% decrease in the value of GAIR
immediately after the procedure, which increased to 40% at 3 hours
following treatment. The authors suggest that once real-time
monitoring of GAIR is feasible, the utilization of this method in
clinical settings will allow intraprocedure evaluation of IRE
efﬁcacy.101
In conclusion, IRE is a novel minimally invasive tumor/tissue
ablation technique with several recognized advantages: (1) pres-
ervation of surrounding vital structures such as vessels; (2) not
affected by the heat-sink effect; (3) apoptotic, nonnecrotic, cell
death with a quick tissue regeneration; (4) a shorter procedure
time; and (5) able to perform under real-time monitoring. How-
ever, the history of IRE ablation research and development is still at
its infancy and therefore, additional investigations are absolutely
crucial to further understand and optimize this technique to
improve the clinical outcomes and safety.
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